Q
Quant'AbondanceL'abondance, quantifiée.

Actualités

Uniquement les titres à fort signal - événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.

24,258 signal articles · 39 in last 24h · 115,255 total before filter · latest 2h ago
39last 24h
1801last 7d
299● bullish (7d)
170● bearish (7d)
205publishers
AllMacro322Earnings850M&A104Regulatory25Product16Analyst25
✕ clear all filtersticker: CVSSentiment:bullishneutralbearish✓ showing all (incl. clickbait)
Mizuho Raises CVS Health (CVS) Price Target on More Stable Policy Environment
Insider Monkey62d agoneutral
Mizuho Raises CVS Health (CVS) Price Target on More Stable Policy Environment

With an annual dividend yield of 2.65%, CVS Health Corporation (NYSE:CVS) is included among the 12 High Yield Fortune 500 Stocks to Buy Now. America’s leading health solutions company, CVS Health Corporation (NYSE:CVS), provides advanced health care from pharmacy services and health plans to health and wellness. On June 8, Mizuho upped its price target on […]

CVS Health (CVS) Price Target Boosted by $8 at Mizuho
Insider Monkey83d agoneutral
CVS Health (CVS) Price Target Boosted by $8 at Mizuho

With an annual dividend yield of 2.84%, CVS Health Corporation (NYSE:CVS) is included among the 12 Best Dividend Stocks to Invest in According to Hedge Funds. America’s leading health solutions company, CVS Health Corporation (NYSE:CVS) provides advanced health care from pharmacy services and health plans to health and wellness. On May 20, Mizuho bumped up its price […]

CVS Health (CVS) Price Target Boosted by $1
Insider Monkey95d agoneutral
CVS Health (CVS) Price Target Boosted by $1

With an annual dividend yield of 2.88%, CVS Health Corporation (NYSE:CVS) is included among the 12 Best Blue Chip Dividend Stocks to Buy Now. America’s leading health solutions company, CVS Health Corporation (NYSE:CVS) provides advanced health care from pharmacy services and health plans to health and wellness. On May 8, Wells Fargo analyst Stephen Baxter slightly raised […]